Healthcare of Ontario Pension Plan Trust Fund Trims Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Healthcare of Ontario Pension Plan Trust Fund lessened its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) by 13.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 338,400 shares of the company's stock after selling 51,200 shares during the quarter. Healthcare of Ontario Pension Plan Trust Fund owned about 0.89% of Tarsus Pharmaceuticals worth $11,130,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in TARS. Quest Partners LLC purchased a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at $61,000. Canada Pension Plan Investment Board purchased a new position in shares of Tarsus Pharmaceuticals in the 2nd quarter worth $114,000. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company's stock worth $166,000 after buying an additional 1,530 shares in the last quarter. FMR LLC increased its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the 3rd quarter. FMR LLC now owns 5,032 shares of the company's stock worth $166,000 after buying an additional 3,537 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new stake in shares of Tarsus Pharmaceuticals during the 2nd quarter valued at about $202,000. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Up 3.2 %

Shares of TARS traded up $1.61 during mid-day trading on Friday, reaching $52.45. 290,714 shares of the company's stock traded hands, compared to its average volume of 723,093. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock's 50-day moving average is $41.05 and its two-hundred day moving average is $33.41. Tarsus Pharmaceuticals, Inc. has a 12 month low of $15.60 and a 12 month high of $52.99. The stock has a market cap of $2.01 billion, a P/E ratio of -13.77 and a beta of 1.00.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TARS. William Blair raised Tarsus Pharmaceuticals to a "strong-buy" rating in a research note on Friday, August 30th. The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a "neutral" rating in a report on Friday, November 15th. Finally, Oppenheimer increased their price target on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an "outperform" rating in a report on Thursday, November 14th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $54.20.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.